이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Newron Pharmaceuticals 관리

관리 기준 확인 3/4

Newron Pharmaceuticals' CEO는 Stefan Weber, Jun2012 에 임명되었습니다 의 임기는 12.42 년입니다. 총 연간 보상은 € 510.00K, 93.1% 로 구성됩니다. 93.1% 급여 및 6.9% 보너스(회사 주식 및 옵션 포함). 는 CHF 223.05K 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 223.05K. 경영진과 이사회의 평균 재임 기간은 각각 12 년과 12.4 년입니다.

주요 정보

Stefan Weber

최고 경영자

€510.0k

총 보상

CEO 급여 비율	93.1%
CEO 임기	12.1yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	12.1yrs
이사회 평균 재임 기간	12.5yrs

최근 관리 업데이트

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

Recent updates

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25

CEO 보상 분석

Stefan Weber 의 보수는 Newron Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	€510k	€475k	-€16m
Sep 30 2023	n/a	n/a	-€16m
Jun 30 2023	n/a	n/a	-€16m
Mar 31 2023	n/a	n/a	-€17m
Dec 31 2022	€498k	€429k	-€17m
Sep 30 2022	n/a	n/a	-€16m
Jun 30 2022	n/a	n/a	-€14m
Mar 31 2022	n/a	n/a	-€15m
Dec 31 2021	€510k	€414k	-€15m
Sep 30 2021	n/a	n/a	-€17m
Jun 30 2021	n/a	n/a	-€20m
Mar 31 2021	n/a	n/a	-€20m
Dec 31 2020	€582k	€403k	-€21m
Sep 30 2020	n/a	n/a	-€19m
Jun 30 2020	n/a	n/a	-€17m
Mar 31 2020	n/a	n/a	-€18m
Dec 31 2019	€691k	€440k	-€20m
Sep 30 2019	n/a	n/a	-€21m
Jun 30 2019	n/a	n/a	-€21m
Mar 31 2019	n/a	n/a	-€18m
Dec 31 2018	€647k	€430k	-€15m
Sep 30 2018	n/a	n/a	-€15m
Jun 30 2018	n/a	n/a	-€14m
Mar 31 2018	n/a	n/a	-€10m
Dec 31 2017	€563k	€418k	-€5m

보상 대 시장: Stefan 의 총 보상 ($USD 548.03K ) Swiss 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 952.15K ).

보상과 수익: 회사가 수익성이 없는 동안 Stefan 의 보상이 증가했습니다.

CEO

Stefan Weber (59 yo)

12.1yrs

테뉴어

€510,000

보상

Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stefan Weber	CEO & Executive Director	12.1yrs	€510.00k	0.11% € 160.8k
Roberto Galli	Chief Financial Officer	12.1yrs	데이터 없음	0.013% € 19.8k
Filippo Moriggia	Vice President of Operations	2yrs	데이터 없음	데이터 없음
Ravi Anand	Chief Medical Officer	19.2yrs	€1.12m	0.22% € 330.8k
Laura Faravelli	Vice President of Business Development	less than a year	데이터 없음	데이터 없음

12.1yrs

평균 재임 기간

경험이 풍부한 관리: NWRN 의 관리팀은 노련하고 경험 (평균 재직 기간 12 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stefan Weber	CEO & Executive Director	12.5yrs	€510.00k	0.11% € 160.8k
Patrick Langlois	Independent Non-Executive Director	16yrs	€78.00k	0.063% € 94.8k
Ulrich Köstlin	Independent Non-Executive Chairman	11.3yrs	€106.00k	0.21% € 318.0k
Luca Benatti	Non-Executive & Independent Director	10.3yrs	€68.00k	데이터 없음
Ze' Seltzer	Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
Charles Olanow	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Fabrizio Stocchi	Member of Scientific and Clinical Advisory Board	no data	데이터 없음	데이터 없음
Emilio Perucca	Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
Paolo Marchettini	Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
Marco Onofrj	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Abraham Lieberman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Murphy	Chairman of the Board of Statutory Auditors	22.5yrs	€13.00k	데이터 없음

12.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: NWRN 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12.4 년).

Newron Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Forecast breakeven date pushed back to 2026

Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Consensus revenue estimates fall by 19%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2025

Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia (TRS)

Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide

Newron Pharmaceuticals S.p.A. to Report Fiscal Year 2023 Results on Mar 19, 2024

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

New minor risk - Market cap size

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: €0.98 loss per share (vs €0.83 loss in FY 2021)

Newron Reports Striking One-Year Interim Efficacy Results from Its Phase Ii Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Announces Striking Six-Month Interim Results from Its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

First half 2022 earnings released: €0.48 loss per share (vs €0.51 loss in 1H 2021)

Newron Pharmaceuticals S.P.A. Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia (Trs) At the 33Rd Cinp Hybrid World Congress of Neuropsychopharmacology

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

First half 2021 earnings released: €0.51 loss per share (vs €0.59 loss in 1H 2020)

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA Filings for Xadago® (safinamide) in the USA

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2020 earnings released: €1.18 loss per share (vs €1.13 loss in FY 2019)

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 13, 2021

Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Disease Patients

New 90-day high: CHF2.99

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

New 90-day high: CHF2.95

Newron Pharmaceuticals Completes Enrollment of Explanatory Safety and Efficacy Study with Evenamide in Schizophrenia Patients

New 90-day high: CHF2.25

New 90-day high: CHF2.11

Analysts lower EPS estimates to -€1.17

First half earnings released

New 90-day low - CHF1.55

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령